Literature DB >> 29095412

Cervical Sagittal Range of Motion as a Predictor of Symptom Severity in Cervical Spondylotic Myelopathy.

Kristen J Nicholson1, Paul W Millhouse1,2, Emily Pflug2, Barrett Woods1,2, Gregory D Schroeder1,2, D Greg Anderson1,2, Alan S Hilibrand1,2, Christopher K Kepler1,2, Mark F Kurd1,2, Jeffrey A Rihn1,2, Alexander Vaccaro1,2, Kris E Radcliff1,2.   

Abstract

STUDY
DESIGN: A retrospective review of radiographic data and functional outcomes.
OBJECTIVE: The aim of this study was to evaluate whether myelopathy symptom severity upon presentation corresponds to sagittal plane alignment or nonmyelopathy symptoms, such as pain, in patients with cervical spondylotic myelopathy (CSM). SUMMARY OF BACKGROUND DATA: Cervical sagittal balance is an important parameter in the outcome of surgical reconstruction. However, the effect of sagittal alignment on symptom severity in patients who have not undergone spine surgery is not well defined.
METHODS: A consecutive series of CSM patients was identified at an academic institution. Preoperative radiographs were analyzed for sagittal vertical axis (C2SVA), C7 slope (C7S), C2-C7 angle in neutral (C27N), flexion (C27F), and extension (C27E), and range of motion (C27ROM). Neutral alignment was categorized as lordotic, kyphotic, or sigmoid/straight. Outcomes collected were SF-12, neck disability index, arm pain, neck pain, and modified JOA (mJOA). Pearson coefficients determined correlations between radiographic and outcome parameters. Multivariate regression evaluated predictive factors of mJOA.
RESULTS: Radiographic parameters did not correlate with pain. Increasing age, smaller C27ROM, and smaller flexion angles correlated to lower (more severe) baseline mJOA scores. ROM (and not static alignment) was the only significant predictor of mJOA in the multivariate regression. Despite significant radiographic differences between lordotic, kyphotic, and sigmoid/straight alignment groups, myelopathy severity did not differ between these groups.
CONCLUSION: Static, neutral alignment, including SVA and lordosis, did not correlate with myelopathy or pain symptoms. Greater C27ROM and increased maximal flexion corresponded to milder myelopathy symptoms, suggesting that patients with myelopathy may compensate for cervical stenosis with hyperflexion, similar to that which is observed in the lumbar spine. In a CSM patient population, dynamic motion and compensatory deformities may play a more significant role in myelopathy symptom severity than what can be discerned from standard, neutral position radiographs. LEVEL OF EVIDENCE: 3.

Entities:  

Mesh:

Year:  2018        PMID: 29095412     DOI: 10.1097/BRS.0000000000002478

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  4 in total

Review 1.  Risk factors for the development of degenerative cervical myelopathy: a review of the literature.

Authors:  Guillaume Baucher; Jelena Taskovic; Lucas Troude; Granit Molliqaj; Aria Nouri; Enrico Tessitore
Journal:  Neurosurg Rev       Date:  2021-11-30       Impact factor: 3.042

2.  Telemedicine in research and training: spine surgeon perspectives and practices worldwide.

Authors:  Karim Shafi; Francis Lovecchio; Grant J Riew; Dino Samartzis; Philip K Louie; Niccole Germscheid; Howard S An; Jason Pui Yin Cheung; Norman Chutkan; Gary Michael Mallow; Marko H Neva; Frank M Phillips; Daniel M Sciubba; Mohammad El-Sharkawi; Marcelo Valacco; Michael H McCarthy; Melvin C Makhni; Sravisht Iyer
Journal:  Eur Spine J       Date:  2021-01-22       Impact factor: 3.134

3.  The Pre-Operative Duration of Symptoms: The Most Important Predictor of Post-Operative Efficacy in Patients with Degenerative Cervical Myelopathy.

Authors:  Shengyu Guo; Taotao Lin; Rongcan Wu; Zhenyu Wang; Gang Chen; Wenge Liu
Journal:  Brain Sci       Date:  2022-08-17

4.  Impact of cervical sagittal parameters on axial neck pain in patients with cervical kyphosis.

Authors:  Jia Li; Di Zhang; Yong Shen
Journal:  J Orthop Surg Res       Date:  2020-09-22       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.